Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg sustained‑release intravitreal implant for intravitreal use. It is indicated for the treatment of diabetic macular edema in adult patients.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology clinics and procurement teams worldwide, providing reliable access to this specialty ophthalmic product. The company adheres to stringent quality standards and supports regulatory compliance in all target markets. Our distribution network ensures timely delivery and appropriate storage conditions.

Iluvien (fluocinolone acetonide) is used to manage diabetic macular edema, a chronic retinal condition.

Diabetic macular edema: reduces retinal thickness, decreases fluid accumulation, and helps stabilise or improve visual acuity in affected eyes. Persistent diabetic macular edema after prior therapy: delivers continuous low‑dose corticosteroid directly to the vitreous, providing up to 36 months of treatment without repeated injections. Chronic diabetic macular edema in adults: maintains macular structural integrity, limits disease progression, and reduces the need for additional pharmacologic interventions.

Iluvien may be associated with ocular adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Increased intraocular pressure - Cataract formation or progression - Ocular pain or discomfort after implantation - Vitreous floaters or visual disturbances - Conjunctival haemorrhage - Blurred vision

Serious or Rare Side Effects: - Endophthalmitis or severe intraocular infection - Retinal detachment or tear - Persistent IOP elevation requiring surgical intervention - Implant migration or dislocation - Severe ocular inflammation or uveitis - Optic nerve damage or vision loss

Prior to Iluvien implantation, clinicians should evaluate patient suitability and monitor for known risks.

Glaucoma risk assessment: measure baseline intraocular pressure and visual field before implantation. Cataract monitoring: observe lens opacity development in phakic eyes during follow‑up. Infection control: avoid implantation in eyes with active infection or inflammation. Intraocular pressure monitoring: schedule regular IOP checks after the procedure to detect elevation early. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iluvien can interact with other ocular or systemic agents, influencing safety or efficacy.

Major Interactions (Avoid): - Systemic corticosteroids: additive risk of intraocular pressure rise and cataract formation. - Antifungal azoles (e.g., ketoconazole): may increase local steroid concentration, heightening IOP risk. - Intravitreal anti‑VEGF agents administered concurrently: may alter implant positioning or increase inflammation.

Moderate Interactions (Monitor Closely): - Topical NSAID eye drops: monitor for delayed corneal healing. - Other intravitreal drugs (e.g., steroids, antibiotics): stagger administration to avoid overlapping toxicity. - Beta‑blocker eye drops: observe for potential pupil size changes.